<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623064</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30061</org_study_id>
    <secondary_id>EORTC-30061</secondary_id>
    <secondary_id>EUDRACT-2006-002976-16</secondary_id>
    <secondary_id>GSK-EORTC-30061</secondary_id>
    <nct_id>NCT00623064</nct_id>
  </id_info>
  <brief_title>Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer</brief_title>
  <official_title>Phase I Study of Cisplatin, Gemcitabine and Lapatinib as First Line Treatment in Advanced/Metastatic Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as cisplatin, and gemcitabine, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving lapatinib together with combination chemotherapy may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when&#xD;
      given together with cisplatin and gemcitabine as first-line therapy in treating patients with&#xD;
      locally advanced or metastatic urothelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended doses of lapatinib ditosylate when&#xD;
           administered with gemcitabine hydrochloride and cisplatin, and determine on the basis of&#xD;
           acute dose-limiting toxicity in course 1 in patients with locally advanced or metastatic&#xD;
           transitional cell carcinoma of the urothelial tract.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine any relationship between drug exposure and adverse events in these&#xD;
           patients.&#xD;
&#xD;
        -  To assess the antitumor activity in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of lapatinib ditosylate.&#xD;
&#xD;
        -  Lapatinib ditosylate, cisplatin, and gemcitabine hydrochloride: Patients receive oral&#xD;
           lapatinib ditosylate once daily on days 1-28, cisplatin IV on day 2, and gemcitabine&#xD;
           hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in&#xD;
           the absence of disease progression or unacceptable toxicity until the recommended dose&#xD;
           of lapatinib ditosylate is determined.&#xD;
&#xD;
        -  Lapatinib ditosylate, cisplatin, gemcitabine hydrochloride: Subsequently enrolled&#xD;
           patients receive oral lapatinib ditosylate (beginning at one dose level below the&#xD;
           recommended dose determined in the previous combination) once daily on days 1-21,&#xD;
           cisplatin IV on day 1, gemcitabine hydrochloride IV over 30 minutes. Courses repeat&#xD;
           every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      All patients undergo blood sample collection periodically for pharmacokinetic analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed weekly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of lapatinib ditosylate in combination with cisplatin/gemcitabine hydrochloride and cisplatin/gemcitabine hydrochloride based on the documentation of the acute dose-limiting toxicity in course 1</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of lapatinib ditosylate in combination with cisplatin/gemcitabine hydrochloride and cisplatin/gemcitabine hydrochloride</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity according to RECIST</measure>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven transitional cell carcinoma of the urothelial tract&#xD;
&#xD;
               -  Metastatic or locally advanced disease&#xD;
&#xD;
          -  Measurable disease according to RECIST&#xD;
&#xD;
               -  Involvement of at least one target not in previously irradiated fields&#xD;
&#xD;
          -  Overexpressing HER1 and/or HER2 receptors (HER2 3+ by IHC OR HER2 FISH or CISH&#xD;
             positive)&#xD;
&#xD;
          -  No clinical signs of CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Thrombocytes &gt; 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT ≤ 3 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-barrier contraception during and for 3&#xD;
             months after completion of study treatment&#xD;
&#xD;
          -  Cardiac ejection fraction normal&#xD;
&#xD;
          -  Normal 12 lead ECG&#xD;
&#xD;
          -  No serious cardiac illness or medical condition within the past 6 months including,&#xD;
             but not limited to, any of the following:&#xD;
&#xD;
               -  Documented congestive heart failure&#xD;
&#xD;
               -  High-risk uncontrolled arrhythmias&#xD;
&#xD;
               -  Angina pectoris requiring antianginal medication&#xD;
&#xD;
               -  Clinically significant valvular heart disease&#xD;
&#xD;
               -  Evidence of transmural infarction on ECG&#xD;
&#xD;
               -  Poorly controlled hypertension (e.g., systolic blood pressure [BP] &gt; 180 mm Hg or&#xD;
                  diastolic BP &gt; 100 mm Hg)&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  No other malignancy within the past 3 years except basal cell or squamous cell&#xD;
             carcinoma of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active or uncontrolled infections, serious illnesses, malabsorption syndrome or&#xD;
             medical conditions, hepatitis, HIV, and/or cirrhosis&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering study protocol compliance or follow-up schedule&#xD;
&#xD;
          -  No current active hepatic or biliary disease (with the exception of Gilbert's&#xD;
             syndrome, asymptomatic gallstones, liver metastases or stable chronic liver metastases&#xD;
             or stable chronic liver disease)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from any effects of surgery&#xD;
&#xD;
          -  Intravesicle therapy for superficial disease allowed&#xD;
&#xD;
          -  Prior neoadjuvant or adjuvant chemotherapy allowed&#xD;
&#xD;
               -  Must have a minimum interval of six months between the completion of neoadjuvant&#xD;
                  or adjuvant chemotherapy and the diagnosis of metastatic disease&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No radiotherapy within the past 4 weeks&#xD;
&#xD;
          -  No drugs and herbal inducers or inhibitors of CYP3A4 (e.g., bergamottin or glabridin)&#xD;
             within 10 days prior to study treatment and while receiving lapatinib ditosylate&#xD;
             therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No concurrent treatment with other investigational therapy for other diseases or&#xD;
             conditions&#xD;
&#xD;
          -  No concurrent prophylactic antibiotics&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF)&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent herbal or dietary supplements&#xD;
&#xD;
          -  No concurrent consumption of grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gedske Daugaard, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

